Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Peptic Ulcer Disease III: Clinical Manifestations and Complications

Duodenal UlcersDuodenal ulcers are the most common form of peptic ulcer disease, presenting with chronic, intermittent epigastric pain. Pain typically appears 2–3 hours after meals, especially when the stomach is empty, often waking patients at night. It is characteristically relieved by food or antacids (“pain–food–relief”). Some patients remain asymptomatic until complications like bleeding or perforation emerge, particularly with NSAID or anticoagulant use.Gastric UlcersGastric ulcers share...

Inflammatory Bowel Disease II: Ulcerative Colitis

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Translated article] New Prevention Measures in Venereology: Evidence Review on the DoxiPrEP/PEP Antibiotic and the 4CMenB Vaccine.

Actas dermo-sifiliograficas·2025

Same author

New Prevention Measures in Venereology: Evidence Review on the DoxiPrEP/PEP Antibiotic and the 4CMenB Vaccine.

Actas dermo-sifiliograficas·2025

Same author

Vulval Lymphangioma Circumscriptum as Painful Papulovesicles Mimicking Genital Warts.

Actas dermo-sifiliograficas·2024

Same author

[Translated article] Expert Recommendations from the AEDV on Legal Aspects Surrounding the Management of Sexually Transmitted Diseases.

Actas dermo-sifiliograficas·2024

Same author

Expert Recommendations from the AEDV on Legal Aspects Surrounding the Management of Sexually Transmitted Diseases.

Actas dermo-sifiliograficas·2024

Same author

Vulval Lymphangioma Circumscriptum as Painful Papulovesicles Mimicking Genital Warts.

Actas dermo-sifiliograficas·2023

Search research articles

Related Experiment Video

Updated: May 12, 2026

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

Bullous pemphigoid: clinical practice guidelines.

I Fuertes de Vega¹, P Iranzo-Fernández², J M Mascaró-Galy²

¹Servicio de Dermatología, Hospital Parc Taulí de Sabadell, Universidad Autónoma de Barcelona, Sabadell, España.

Actas Dermo-Sifiliograficas

|April 2, 2013

Summary

This summary is machine-generated.

Bullous pemphigoid (BP) is a common autoimmune blistering disease affecting older adults. Recent advances offer better diagnosis and treatment, but international management guidelines are still lacking.

Keywords:

Ampolla subepidérmica Autoimmune blistering diseases Bullous pemphigoid Enfermedades ampollosas autoinmunes Fármacos inmunosupresores Guías de manejo terapéutico Immunosuppressive agents Penfigoide ampolloso Subepidermal blister Treatment and management guidelines

More Related Videos

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

Related Experiment Videos

Last Updated: May 12, 2026

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

Granulocyte-dependent Autoantibody-induced Skin Blistering

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

Area of Science:

Dermatology
Immunology
Autoimmune Diseases

Background:

Bullous pemphigoid (BP) is a prevalent autoimmune subepidermal blistering disease.
Autoantibodies target basement membrane components, primarily BP180 and BP230 hemidesmosomal proteins.
BP predominantly affects the elderly, with an incidence of 0.2-3 per 100,000 in Spain.

Purpose of the Study:

To provide an updated review of bullous pemphigoid treatments.
To focus on evidence-based recommendations for practical management.
To address the lack of international consensus on BP management guidelines.

Main Methods:

Review of current scientific literature on bullous pemphigoid treatment.
Focus on evidence-based recommendations and practical clinical experience.
Inclusion of recent advances in diagnostic techniques and therapeutic targets.

Main Results:

Advances in diagnostics like ELISA for BP180 enhance disease identification.
New therapeutic agents with diverse targets are emerging for BP treatment.
Despite progress, a unified international guideline for BP management remains absent.

Conclusions:

Improved understanding and management of bullous pemphigoid are ongoing.
Evidence-based recommendations are crucial for routine clinical practice.
Further development of international consensus is needed for optimal patient care.